Ubs Group Ag Revance Therapeutics, Inc. Call Options Transaction History

Ubs Group Ag

3 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2023 May 12, 2023	SELL	$18.36 - $35.27 $3.67 Million - $7.05 Million	-200,000 Reduced 74.07%	70,000 $2.25 Million
Q4 2022 Feb 08, 2023	BUY	$18.32 - $30.66 $4.95 Million - $8.28 Million	270,000 New	270,000 $4.98 Million
Q4 2019 Feb 14, 2020	BUY	$11.66 - $20.15 $366,124 - $632,710	31,400 New	31,400 $510,000

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.